Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 514148Generated: October 30, 2026

Potassium Carbonate → 2-Tert-butoxy-2-(1-(4-chlorophenyl)-3-methyl-4-(2-oxo-1,2-dihydropyrimidin-5-yl)naphthalen-2-yl)acetic acid

https://huagongshe.com/reaction/514148

Reaction equation

Participants

RoleNameHCIDCharge
ReactantPotassium CarbonateHCID 11430—
ReactantPotassium FluorideHCID 522689—
Reactant2-Hydroxypyrimidine-5-boronic acidHCID 17750423—
ReactantMethyl 2-(4-bromo-1-(4-chlorophenyl)-3-methylnaphthalen-2-yl)-2-tert-butoxyacetateHCID 67126267—
CatalystBis(cyclopenta-1,4-dien-1-yl(diphenyl)phosphane);dichloropalladium;iron(2+)HCID 178418228—
SolventAcetic AcidHCID 176—
SolventEthanolHCID 702—
SolventWaterHCID 962—
SolventTolueneHCID 1140—
SolventTetrahydrofuranHCID 8028—
Product2-Tert-butoxy-2-(1-(4-chlorophenyl)-3-methyl-4-(2-oxo-1,2-dihydropyrimidin-5-yl)naphthalen-2-yl)acetic acidHCID 6712618636.1%

Reaction Conditions

Temperature100 °C

Reaction Steps

A suspension methyl 2-(4-bromo-1-(4-chlorophenyl)-3-methylnaphthalen-2-yl)-2-tert-butoxyacetate (10.5 mg, 22.1 μmol), [1H]pyrimidin-2-one-5-yl-boronic acid (25 mg, 0.11 mmol), PdCl2(dppf) (3.2 mg, 4.4 μmol), K2CO3 (46 mg, 0.33 mmol), PhMe (500 μL), EtOH (absolute, 250 μL), and H2O (250 μL) was heated to 100° C. for 30 min, but conversion was poor. The reaction was treated with glacial AcOH (60 μL, 1.05 mmol) and KF (40 mg, 0.688 mmol). More PdCl2(dppf) (3.2 mg, 4.4 μmol) and [1H]pyrimidin-2-one-5-yl-boronic acid (7 mg, 30 μmol) were added and the reaction was heated to 100° C. After 2 h, the reaction was added to H2O (15 mL) and glacial AcOH (0.2 mL). The system was extracted with EtOAc (3×10 mL). Combined organic phases were dried (Na2SO4), filtered, and concentrated. The crude material was treated with THF (750 μL), EtOH (absolute, 750 μL), H2O (500 μL), and LiOH monohydrate (50 mg 1.2 mmol). The suspension was heated to 100° C. for 30 min. The reaction was cooled to 23° C., filtered through a 0.45 micron filter, and directly purified by reverse phase HPLC (Gemini, 5 to 100% ACN/H2O+0.1% TFA). The product-containing fractions were combined and lyophilized, giving the title compound (parent form) (3.8 mg, 36% over 2 steps). 1H-NMR: (400 MHz, DMSO-d6): δ 12.8 (s, broad, 1H), 8.29 (app. s, broad, 1H), 7.75-7.68 (m, 2H), 7.58-7.44 (m, 4H), 7.43-7.38 (m, 2H), 7.25 (d, J=8.2 Hz, 1H), 5.12 (s, 1H), 2.38 (s, 3H), 0.96 (s, 9H). LCMS-ESI+ (m/z): [M+H]+ calcd for C27H26ClN2O4: 477.2; Found: 477.2.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS09102614B2
Source datasetuspto-grants-2015_08
ORD IDord-f9a280a9a1ec41359792fe24e264b20f
Source noteuspto-grants-2015_08